Pfizer spinoff Zoetis, the animal health company, added a second director to its board under a deal it reached earlier this year with activist investor Bill Ackman and his firm Pershing Square Capital Management.
Actavis CEO Paul Bisaro has been on a roll lately. He's scored one M&A deal after another, with Warner Chilcott wrapping up last year and Forest Laboratories currently on deck. And his pocketbook has shared in the bounty.
As the dust settles around Actavis' announced buyout of Warner Chilcott, it's time to dig into some of the nitty-gritty details about "New Actavis." For instance, which of Warner's top people will stick around--and if they don't, how much severance might they collect on the way out? And just how big is the tax cut Actavis expects from making the deal?
Actavis and Warner Chilcott have struck a deal. And it's bigger than the $5 billion-or-so that was bandied about while the companies negotiated. About $3 billion bigger, in fact: According to Actavis, the company will acquire Warner in a stock swap worth $8.5 billion.
Call it a rite of spring. Every year about this time, FiercePharma takes a look at executive compensation in the industry, and we rank the highest-paid CEOs. If you're a regular reader, you'll notice that this year's list is longer than previous editions. And there's a reason for that: curiosity. Check out the report >>
Who in this business hasn't seen billions incinerated in pursuit of sheer folly? Influential today is the savvy executive who can marshal experts as well as financial resources in pursuit of a smarter, better, faster way to develop and market important new drugs. And intelligent research strategies are far more rare than we acknowledge. You'll find some here in our second annual report on the 25 most influential people in the industry (find last year's report here). Check out the list >>
Watson Pharmaceuticals is no more. The generic drug company has officially taken the name of its most recent acquisition target, Actavis, thinking it has better brand recognition in the markets where it intends to expand.
The generic world was abuzz yesterday after rumors surfaced that Watson Pharmaceuticals could buy Actavis for about $7 billion.
Paul Bisaro has made no secret of his branded ambitions for Watson Pharmaceuticals ($WPI). The drugmaker, which now focuses mostly on generics, is looking to remake itself as a brand-and-generics
Watson Pharmaceuticals scored a victory in its effort to branch out of its generic drug business and launch new branded therapies with today's announcement that it has won regulatory approval to